Trial Profile

A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMGN 289 (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors ImmunoGen

Most Recent Events

24 Apr 2015 Status changed from recruiting to discontinued according to an ImmunoGen media release.
25 Apr 2014 Dose escalation is ongoing in this trial, according to an ImmunoGen media release.
31 Jan 2014 Data presentation and/or development decisions for IMGN-289 are anticipated in the second half of 2014, according to an ImmunoGen media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com